Direkte orale antikoagulantia til behandling af cancerassocieret trombose

Maja Hellfritzsch Poulsen; Thomas Kümler; Morten Kjøbek Lamberts; Christina Halgaard Ruhlmann; Erik Lerkevang Grove

doi:10.61409/V04240299

Direkte orale antikoagulantia til behandling af cancerassocieret trombose

Maja Hellfritzsch Poulsen, Thomas Kümler, Morten Kjøbek Lamberts, Christina Halgaard Ruhlmann, Erik Lerkevang Grove

Abstract

Cancer-associated thrombosis (CAT) remains a challenging aspect of managing patients with cancer. This review discusses evidence regarding anticoagulants in the treatment of CAT, with particular emphasis on direct oral anticoagulants (DOAC). Apixaban, rivaroxaban and edoxaban have proven attractive alternatives to low-molecular weight heparins, and interactions with medical cancer treatment does not pose a major challenge. The majority of guidelines have endorsed the use of DOAC, and we highlight points to consider when choosing the optimal anticoagulant for the individual patient.

Bidragets oversatte titel	Direct oral anticoagulants for the treatment of cancer-associated thrombosis
Originalsprog	Dansk
Artikelnummer	V04240299
Tidsskrift	Ugeskrift for Laeger
Vol/bind	186
Udgave nummer	42
ISSN	0041-5782
DOI	https://doi.org/10.61409/V04240299
Status	Udgivet - 14 okt. 2024

Emneord

Humans
Neoplasms/complications
Anticoagulants/administration & dosage
Pyridones/therapeutic use
Administration, Oral
Thrombosis/drug therapy
Rivaroxaban/therapeutic use
Pyridines/therapeutic use
Thiazoles/therapeutic use
Pyrazoles/therapeutic use
Factor Xa Inhibitors/therapeutic use

Adgang til dokumentet

10.61409/V04240299Licens: CC BY-NC-ND

Andre filer og links

Link to publication in Scopus

Citationsformater

@article{da8d12e775934d0c8f3e31a3c101229e,

title = "Direkte orale antikoagulantia til behandling af cancerassocieret trombose",

abstract = "Cancer-associated thrombosis (CAT) remains a challenging aspect of managing patients with cancer. This review discusses evidence regarding anticoagulants in the treatment of CAT, with particular emphasis on direct oral anticoagulants (DOAC). Apixaban, rivaroxaban and edoxaban have proven attractive alternatives to low-molecular weight heparins, and interactions with medical cancer treatment does not pose a major challenge. The majority of guidelines have endorsed the use of DOAC, and we highlight points to consider when choosing the optimal anticoagulant for the individual patient.",

keywords = "Humans, Neoplasms/complications, Anticoagulants/administration & dosage, Pyridones/therapeutic use, Administration, Oral, Thrombosis/drug therapy, Rivaroxaban/therapeutic use, Pyridines/therapeutic use, Thiazoles/therapeutic use, Pyrazoles/therapeutic use, Factor Xa Inhibitors/therapeutic use",

author = "Poulsen, {Maja Hellfritzsch} and Thomas K{\"u}mler and Lamberts, {Morten Kj{\o}bek} and Ruhlmann, {Christina Halgaard} and Grove, {Erik Lerkevang}",

note = "Published under Open Access CC-BY-NC-BD 4.0. https://creativecommons.org/licenses/by-nc-nd/4.0/.",

year = "2024",

month = oct,

day = "14",

doi = "10.61409/V04240299",

language = "Dansk",

volume = "186",

journal = "Ugeskrift for Laeger",

issn = "0041-5782",

publisher = "Almindelige Danske Laegeforening",

number = "42",

}

TY - JOUR

T1 - Direkte orale antikoagulantia til behandling af cancerassocieret trombose

AU - Poulsen, Maja Hellfritzsch

AU - Kümler, Thomas

AU - Lamberts, Morten Kjøbek

AU - Ruhlmann, Christina Halgaard

AU - Grove, Erik Lerkevang

N1 - Published under Open Access CC-BY-NC-BD 4.0. https://creativecommons.org/licenses/by-nc-nd/4.0/.

PY - 2024/10/14

Y1 - 2024/10/14

N2 - Cancer-associated thrombosis (CAT) remains a challenging aspect of managing patients with cancer. This review discusses evidence regarding anticoagulants in the treatment of CAT, with particular emphasis on direct oral anticoagulants (DOAC). Apixaban, rivaroxaban and edoxaban have proven attractive alternatives to low-molecular weight heparins, and interactions with medical cancer treatment does not pose a major challenge. The majority of guidelines have endorsed the use of DOAC, and we highlight points to consider when choosing the optimal anticoagulant for the individual patient.

AB - Cancer-associated thrombosis (CAT) remains a challenging aspect of managing patients with cancer. This review discusses evidence regarding anticoagulants in the treatment of CAT, with particular emphasis on direct oral anticoagulants (DOAC). Apixaban, rivaroxaban and edoxaban have proven attractive alternatives to low-molecular weight heparins, and interactions with medical cancer treatment does not pose a major challenge. The majority of guidelines have endorsed the use of DOAC, and we highlight points to consider when choosing the optimal anticoagulant for the individual patient.

KW - Humans

KW - Neoplasms/complications

KW - Anticoagulants/administration & dosage

KW - Pyridones/therapeutic use

KW - Administration, Oral

KW - Thrombosis/drug therapy

KW - Rivaroxaban/therapeutic use

KW - Pyridines/therapeutic use

KW - Thiazoles/therapeutic use

KW - Pyrazoles/therapeutic use

KW - Factor Xa Inhibitors/therapeutic use

UR - http://www.scopus.com/inward/record.url?scp=85209476291&partnerID=8YFLogxK

U2 - 10.61409/V04240299

DO - 10.61409/V04240299

M3 - Tidsskriftartikel

C2 - 39531021

SN - 0041-5782

VL - 186

JO - Ugeskrift for Laeger

JF - Ugeskrift for Laeger

IS - 42

M1 - V04240299

ER -

Direkte orale antikoagulantia til behandling af cancerassocieret trombose

Abstract

Emneord

Adgang til dokumentet

Andre filer og links

Fingeraftryk

Citationsformater